UroGen Pharma (URGN) Cash from Operations Growth (3y) (2020 - 2026)

UroGen Pharma (URGN) Cash from Operations Growth (3y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -0.27%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -7.35%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 52.90%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -2.09%
7 Royalty Pharma 33.72 Bn 35.84 Bn - 6.22%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 96.08%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 10.23%
10 UroGen Pharma 2.36 Bn 2.25 Bn 65.88 Mn -17.64%

Historic Data

Download Data
DateValue
Jun 30, 2026 -17.64%
Mar 31, 2026 -20.64%
Dec 31, 2025 -20.78%
Sep 30, 2025 -33.89%
Jun 30, 2025 -18.06%
Mar 31, 2025 -20.54%
Dec 31, 2024 12.12%
Sep 30, 2024 -14.40%
Jun 30, 2024 -7.82%
Mar 31, 2024 -5.02%
Dec 31, 2023 15.11%
Sep 30, 2023 11.64%
Jun 30, 2023 5.38%
Mar 31, 2023 10.20%
Dec 31, 2022 5.77%
Sep 30, 2022 -12.02%
Jun 30, 2022 -18.47%
Mar 31, 2022 -10.19%
Dec 31, 2021 -24.97%
Sep 30, 2021 -25.81%